...61例接受英夫利西单抗(infliximab,ifx)治疗的 cd患者的临床资料,以期为临床应用ifx提供参考。 一、对象与方法 到临床缓解(cdai≥150)即判为诱导缓解..
基于16个网页-相关网页
观察临床缓解率、副反应率及复发率。
Observation of the clinical remission rate, adverse effects and recurrence rate were carried out.
观察临床缓解率、副反应率、复发率及缓解时间。
Clinical remission rate, adverse reaction, recurrence rate and remission period were observed.
观察临床缓解率、不良反应率、复发率及缓解时间。
Clinical remission rate, adverse reaction, recurrence rate and remission time were observed.
应用推荐